Malaysian Genomics Resource
Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services worldwide. Its flagship product, Dtect genetic screening tests which inspects DNA for markers associated with genetic variations that influence various biological processes. The company also offers genome sequencing services for humans, animals, pla… Read more
Malaysian Genomics Resource (0155) - Net Assets
Latest net assets as of September 2025: RM17.43 Million MYR
Based on the latest financial reports, Malaysian Genomics Resource (0155) has net assets worth RM17.43 Million MYR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (RM20.70 Million) and total liabilities (RM3.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | RM17.43 Million |
| % of Total Assets | 84.2% |
| Annual Growth Rate | 0.28% |
| 5-Year Change | 1.26% |
| 10-Year Change | -6.37% |
| Growth Volatility | 45.22 |
Malaysian Genomics Resource - Net Assets Trend (2015–2025)
This chart illustrates how Malaysian Genomics Resource's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Malaysian Genomics Resource (2015–2025)
The table below shows the annual net assets of Malaysian Genomics Resource from 2015 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | RM18.16 Million | -18.76% |
| 2024-06-30 | RM22.35 Million | -16.58% |
| 2023-06-30 | RM26.79 Million | -27.69% |
| 2022-06-30 | RM37.05 Million | +106.62% |
| 2021-06-30 | RM17.93 Million | +74.79% |
| 2020-06-30 | RM10.26 Million | -35.61% |
| 2019-06-30 | RM15.93 Million | -19.42% |
| 2018-06-30 | RM19.77 Million | -18.66% |
| 2017-06-30 | RM24.30 Million | +25.34% |
| 2016-06-30 | RM19.39 Million | +9.85% |
| 2015-06-30 | RM17.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Malaysian Genomics Resource's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3644947000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | RM59.44 Million | 327.37% |
| Total Equity | RM18.16 Million | 100.00% |
Malaysian Genomics Resource Competitors by Market Cap
The table below lists competitors of Malaysian Genomics Resource ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Magontec Ltd
AU:MGL
|
$1.99 Million |
|
Choppies Enterprises Ltd
JSE:CHP
|
$1.99 Million |
|
The Motor & General Finance Limited
NSE:MOTOGENFIN
|
$1.99 Million |
|
HYDROGEN UTOPIA INT.-001
F:D60
|
$1.99 Million |
|
Financiere Marjos SA
PA:FINM
|
$1.99 Million |
|
Presidio Property Trust
NASDAQ:SQFT
|
$1.98 Million |
|
SOCIETE DES BOISSONS DU MAROC
BC:SOCIETE-DES-BOISSONS-DU-MAROC
|
$1.98 Million |
|
Thai Poly Acrylic Public Company Limited
BK:TPA
|
$1.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Malaysian Genomics Resource's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 22,346,760 to 18,155,360, a change of -4,191,400 (-18.8%).
- Net loss of 4,191,390 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | RM-4.19 Million | -23.09% |
| Other Changes | RM-10.00 | -0.0% |
| Total Change | RM- | -18.76% |
Book Value vs Market Value Analysis
This analysis compares Malaysian Genomics Resource's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.97x to 1.51x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-06-30 | RM0.21 | RM0.20 | x |
| 2017-06-30 | RM0.23 | RM0.20 | x |
| 2018-06-30 | RM0.19 | RM0.20 | x |
| 2019-06-30 | RM0.15 | RM0.20 | x |
| 2020-06-30 | RM0.10 | RM0.20 | x |
| 2021-06-30 | RM0.15 | RM0.20 | x |
| 2022-06-30 | RM0.30 | RM0.20 | x |
| 2023-06-30 | RM0.21 | RM0.20 | x |
| 2024-06-30 | RM0.16 | RM0.20 | x |
| 2025-06-30 | RM0.13 | RM0.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Malaysian Genomics Resource utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -75.90%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.23x
- Recent ROE (-23.09%) is below the historical average (-2.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 20.53% | 26.07% | 0.64x | 1.23x | RM1.86 Million |
| 2016 | 8.97% | 16.67% | 0.49x | 1.11x | RM-200.32K |
| 2017 | 2.42% | 5.97% | 0.26x | 1.56x | RM-1.84 Million |
| 2018 | -22.94% | -17.34% | 0.64x | 2.07x | RM-6.51 Million |
| 2019 | -24.10% | -1356.55% | 0.01x | 2.32x | RM-5.43 Million |
| 2020 | 166.70% | 1797.48% | 0.09x | 1.08x | RM16.07 Million |
| 2021 | -23.94% | -240.70% | 0.08x | 1.27x | RM-6.09 Million |
| 2022 | 19.46% | 25.43% | 0.68x | 1.13x | RM3.51 Million |
| 2023 | -53.18% | -170.33% | 0.27x | 1.15x | RM-16.92 Million |
| 2024 | -96.28% | -167.30% | 0.50x | 1.15x | RM-23.75 Million |
| 2025 | -23.09% | -75.90% | 0.25x | 1.23x | RM-6.01 Million |
Industry Comparison
This section compares Malaysian Genomics Resource's net assets metrics with peer companies in the Diagnostics & Research industry.
No peer company data available for comparison.